UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1229-8
Program Prior Authorization/Notification
Medication Nityr® (nitisinone)
P&T Approval Date 9/2017, 9/2018, 9/2019, 9/2020, 9/2021, 9/2022, 9/2023, 9/2024
Effective Date 12/1/2024
1. Background:
Nityr® (nitisinone) is a hydroxyphenyl-pyruvate dioxygenase inhibitor indicated for the treatment
of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with
dietary restriction of tyrosine and phenylalanine.
2. Coverage Criteriaa:
A. Initial Authorization
1. Nityr will be approved based on the following criteria:
a. Diagnosis of hereditary tyrosinemia type 1
-AND-
b. Nityr is being used as an adjunct to diet modification
Authorization will be issued for 12 months.
B. Reauthorization
1. Nityr will be approved based on the following criterion:
a. Patient shows evidence of positive clinical response (e.g., decrease in
urinary/plasma succinylacetone and alpha-1-microglobulin levels) while on Nityr
therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
© 2024 UnitedHealthcare Services, Inc.
1
• Supply limits may be in place.
4. References:
1. Nityr [package insert]. Cambridge, United Kingdom. Cycle Pharmaceuticals Ltd.; January
2024.
Program Prior Authorization/Notification – Nityr (nitisinone) tablets
Change Control
9/2017 New program
9/2018 Annual review with no changes to coverage criteria.
9/2019 Annual review with no changes to coverage criteria. Updated reference.
9/2020 Annual review with no changes to coverage criteria. Updated reference.
9/2021 Annual review. Changed reauthorization approval duration to 12
months. Updated reference.
9/2022 Annual review with no changes to coverage criteria. Added state
mandate disclaimer.
9/2023 Annual review with no changes to coverage criteria. Updated
background.
9/2024 Annual review with no changes. Updated reference.
© 2024 UnitedHealthcare Services, Inc.
2